Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting

THOMSON REUTERS2024-11-11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482786106?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482786106","market":"us","top_or_hot":-1,"title":"Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting","media":"THOMSON REUTERS","content":"<html><body><p>Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting</p></body></html>","source":"reuters_en_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-11 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAYTNNQ:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAYTNNQ:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BYSI","symbol_name":"万春药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUAYTNNQ:1","article_id":"2482786106","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482786106","pubTimestamp":1731330003,"columns":[],"sourceInfo":{"source_id":"reuters_en_live","name":"Thomson Reuters"},"weMediaInfo":null,"summary":"Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembro","collect":0,"end_time":0,"defaultTopTitle":"refinitiv.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BYSI":"万春药业","BK4139":"生物科技"},"translate_title":"Beyondspring在第39届SITC年会上展示了帕博利珠单抗联合普那布林/多西他赛三联IO组合治疗转移性非小细胞肺癌的2期Iit研究的最新疗效结果，此前免疫检查点抑制剂取得了进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BYSI":0.9},"content_text":"Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482786106","isCrawlerRequest":true}